

U. PORTO

FMUP FACULDADE DE MEDICINA
UNIVERSIDADE DO PORTO

MESTRADO INTEGRADO EM MEDICINA

2019/2020

Rita Silveira de Sousa

Abordagem endovascular vs cirurgia aberta nos aneurismas poplíteos:
uma revisão das taxas de preservação de membro e reintervenção

Endovascular vs open repair for popliteal aneurysm: a review on limb
salvage and reintervention rates

Maio, 2020

FMUP

U. PORTO

FMUP FACULDADE DE MEDICINA
UNIVERSIDADE DO PORTO

Rita Silveira de Sousa

Abordagem endovascular vs cirurgia aberta nos aneurismas poplíteos:
uma revisão das taxas de preservação de membro e reintervenção

Endovascular vs open repair for popliteal aneurysm : a review on limb
salvage and reintervention rates

Mestrado Integrado em Medicina

Área: Ciências médicas e da saúde

Tipologia: Monografia

Trabalho efetuado sob a Orientação de:

Doutor Armando Amilcar Pires Mansilha Rodrigues de Almeida

E sob a Coorientação de:

Dr. José Pedro Oliveira Pinto

Trabalho organizado de acordo com as normas da revista:

International Angiology

Maio, 2020

FMUP

Eu, Rita Silveira de Sousa, abaixo assinado, nº mecanográfico 201402872, estudante do 6º ano do Ciclo de Estudos Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, 20/04/2020

Assinatura conforme cartão de identificação:

Rita de Sousa

NOME

Rita Silveira de Sousa

NÚMERO DE ESTUDANTE

201402872

E-MAIL

ritadesousaofficial@hotmail.com

DESIGNAÇÃO DA ÁREA DO PROJECTO

Ciências médicas e da saúde

TÍTULO DISSERTAÇÃO/MONOGRAFIA (riscar o que não interessa)

Endovascular vs open repair for popliteal aneurysm: a review on limb salvage and reintervention rates

ORIENTADOR

Armando Amilcar Pires Mansilha Rodrigues de Almeida

COORIENTADOR (se aplicável)

José Pedro Oliveira Pinto

ASSINALE APENAS UMA DAS OPÇÕES:

É AUTORIZADA A REPRODUÇÃO INTEGRAL DESTA TRABALHO APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE.	<input checked="" type="checkbox"/>
É AUTORIZADA A REPRODUÇÃO PARCIAL DESTA TRABALHO (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº MÁXIMO DE PÁGINAS, ILUSTRAÇÕES, GRÁFICOS, ETC.) APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE.	<input type="checkbox"/>
DE ACORDO COM A LEGISLAÇÃO EM VIGOR, (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº MÁXIMO DE PÁGINAS, ILUSTRAÇÕES, GRÁFICOS, ETC.) NÃO É PERMITIDA A REPRODUÇÃO DE QUALQUER PARTE DESTA TRABALHO.	<input type="checkbox"/>

Faculdade de Medicina da Universidade do Porto, 20/04/2020

Assinatura conforme cartão de identificação: Rita de Sousa

Endovascular vs open repair for popliteal aneurysm: a review on limb salvage and reintervention rates

Rita S. Sousa ^{1 *}, José Oliveira- Pinto ^{2,3,4,5}, Armando Mansilha^{2,3}

¹ Faculty of Medicine of University of Porto, Porto, Portugal; ² Department of Angiology and Vascular Surgery, Centro Hospitalar São João, Porto, Portugal; ³ Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal; ⁴ Cardiovascular R&D Center, Faculty of Medicine of University of Porto, Porto, Portugal; ⁵ Department of Angiology and Vascular Surgery, Hospital CUF Porto, Porto, Portugal

*Corresponding author: Rita S. Sousa, Faculty of Medicine of Porto, Alameda Prof. Hernâni Monteiro ,4200- 319, Porto, Portugal. E-mail: ritadesousaofficial@hotmail.com

ABSTRACT

INTRODUCTION: Open repair remains the gold standard technique for popliteal aneurysm repair. However, the endovascular approach has gained increased popularity. Comparison between these techniques remain crucial to aid the physician choice, yet, data on mid term outcomes lack in literature. The present review aims to compare the limb salvage and reintervention rates in these different approaches.

EVIDENCE ACQUISITION: A comprehensive literature review was conducted to identify publications on endovascular treatment or open repair of popliteal artery aneurysms (PAAs). Primary endpoints were reintervention and limb salvage.

EVIDENCE SYNTHESIS: Twenty-seven studies were selected for analysis describing a total of 5425 patients: 1651 PAAs underwent endovascular repair and 4166 PAAs were treated with open surgery. The technical success rates varied between 83.3 to 100% in the endovascular group and 79 to 100% in the open repair. For endovascular repair, the limb salvage at 1 year ranged between 84.2 and 100%, at 3 years between 88.9 and 100%; and at 5 years between 64.7 and 100%. The reintervention rate at 1 year ranged between 3.7 and 21%, at 3 years between 18.9 and 28%, and at 5 years between 34.5 and 38%. For open repair, the limb salvage varied between 94.3 and 100% at 1 year, 94.5 and 99 % at 3 years, and 86.4 to 97% at 5 years. Regarding the reintervention rate, at 1 year was 12.8 and 13%, at 3 years 3.6 and 12%, and at 5 years varied between 15.7 and 30%.

CONCLUSIONS: Both endovascular and open repair of popliteal aneurysms represent safe options for popliteal aneurysm repair. Yet, on mid-term, open repair is associated with greater limb salvage and fewer reintervention rates. Still, further studies are needed to assess the long-term durability of this technique and its suitability in emergency settings.

Key words: Endovascular procedure; Artery, popliteal; Aneurysm; Limb salvage.

TEXT

Introduction

Popliteal artery aneurysms (PAAs) are the most commonly observed peripheral artery aneurysms ¹, corresponding to 70 % of all the cases ^{2,3}. They are classified as aneurysmal when its diameter is more than 50% its normal measurement ⁴. It affects mostly men and incidence increases with age. PAA occurs frequently bilaterally and may be associated with other peripheral artery aneurysms.

The majority of PAAs present themselves as asymptomatic, often identified incidentally through an imagiologic study, when evaluating another aneurysm ^{5,6} or through routine physical examination. When symptomatic, PAAs can manifest as acute or chronic ischemia ³. Less frequently, patients can present with compressive symptoms. Rupture has rarely been reported ^{7,8}.

There are two different possible approaches: open surgery, in which venous bypass graft is considered the “gold standard” ^{2,9}; or endovascular repair with covered stents, that since its first report, in 1994, has gained popularity ¹⁰.

The comparison between these two therapies is necessary in order to aid the physician selecting the best treatment available and to make individualized choices.

The present review aims to compare the limb salvage and reintervention rates in these different approaches.

Evidence acquisition

The literature in the Medline database was searched for relevant articles published between 2009 and October 2019. The key words used were: “amputation OR limb salvage”, “reintervention OR re-intervention”, “ endovascular OR stent”, “ open surgery” and “popliteal artery aneurysm”, in combination with the Boolean operators AND or OR. Only articles with follow-up data were included and it was only collected data up to 5 years. We excluded all reviews and articles encompassing only women.

Evidence synthesis

Twenty-seven studies, including 5425 patients, were included in the qualitative analysis (Figure 1). Eleven of the included studies compared both techniques (4727 PAAs and 4505

patients), four reported data only for open repair (538 PAAs and 426 patients) and 12 reports focused only on endovascular repair comprising a total of 552 PAAs and 494 patients.

Patient characteristics are depicted in Table I.^{2,3,5-7,11-32}

Endovascular repair

Among the reviewed studies, a total of 1854 stents in 1006 PAAs were implanted.

Regarding the type of stent used the majority of the PAAs were treated with Viabahn-57%, while 6.6% were treated with Hemobahn and 31.4% with Hemobahn/ Viabahn.

The technical success rates reported ranged from 83.3% to 100%^{2,3,7,11-16,18,19,24-26,28-32}.

Nine perioperative deaths were recorded among these studies, accounting for a 30-day mortality between 0% and 6,4%.

Mean follow-up period ranged between 12-68 months after procedure.

The limb salvage at 1 year ranged between 84,2 and 100%^{5-7,14,15,18,25,31}, at 3 years between 88,9% and 100%^{2,3,14,18,28,31}, and at 5 years between 64,7 and 100%^{13,14,16,31,32} (Table III).

Regarding the reintervention rate, at 1 year ranged between 3,7 and 21%^{6,14,17,18,25}, at 3 years between 18.9 and 28%^{2,3,28}, and at 5 years 34,5%³² and 38 %²⁹.

In the emergent setting, limb salvage at 1 year was 82.6%⁵ and 100%¹⁸; and at 3 years was 100%^{18,28}. The reintervention rate at 1 year was 21%¹⁸, and at 3 years was 26.7¹⁸ and 52%²⁸.

Open surgery

Patients submitted to open surgery tended to be younger than the ones submitted to endovascular repair with a mean age varying between 63.5 to 76.3 years in open surgery vs. 68.1 to 81 years in endovascular repair (Table I).

There was a higher percentage of emergent cases assigned to the open repair group (0-43%) in comparison with endovascular repair (0-38.7%). The emergent setting included cases of rupture and acute limb-threatening ischaemia due to chronic thrombosis, acute aneurysmal thrombosis and distal embolization.

Data regarding number of patients included, number of PAAs, perioperative deaths and mean follow –up is depicted in Table II.^{2,3,5-7,11-32}

The technical success rate ranged between 79 and 100%^{20,21,26,29-31}.

Thirteen perioperative deaths were recorded among these studies for open surgery, accounting for a 30 day mortality ranging between 0% and 4.3%.

Follow-up period was heterogeneous among groups, with a median/mean follow-up time ranging between 12 and 137 months after procedure.

The limb salvage ranged at 1 year between 94,3 and 100%^{5,6,25,31}; 3 years between 94,5% and 99%^{28,30,31}; and at 5 years between 86,4% - 97%^{21,22,31,32} (Table III).

Regarding reinterventions, 30-day reintervention rates ranged between 2,1-5,3%^{22,24,27,28,32}, at 1 year was 12,8%⁶ and 13%²⁵, at 3 years was 3.6%³⁰ and 12%²⁸, and at 5 years ranged between 15,7-30%^{21,22,29,32} (Table III).

In the emergent setting, the limb salvage at 1 year was 93.2%⁵ and at 3 years was 100%²⁸. The reintervention rate was 43%²⁸ at 3 years.

Discussion

The present manuscript reviewed the limb salvage and reintervention rates after popliteal aneurysm repair comparing open surgery with the endovascular approach. Although both techniques revealed technically safe and effective for the treatment of popliteal aneurysms, there was a tendency towards a higher limb salvage and lower reintervention rate in the open repair group. In the context of emergency, in comparison with elective repair, the outcomes tend to be worse, with a higher risk of limb loss, complications and reinterventions^{7,21,28}.

Limb salvage following repair of the popliteal aneurysm depend on the runoff status, with a poor distal runoff predicting higher amputation rates^{2,12,28,33}; and on the nature of the patient's symptomatology, with a higher severity increasing the risk of amputation^{22,33,34}. Given that the open repair groups had patients with a more severe presentation and poorer runoff in comparison with endovascular repair, there may even be an underestimation of the real advantage of open surgery.

Regarding the reintervention rates, the endovascular repair group exhibited a higher frequency of reinterventions. Graft thrombosis, restenosis and endoleaks were some of the main causes of reintervention. Although endovascular repair is a less invasive treatment²², associated with shorter hospital stays and a quicker recovery time^{2,35}, more reinterventions along with greater readmissions and costs may be anticipated in the long term²⁷. Furthermore, the lack of long-term data may induce that there could be a even more dramatic difference between the two treatments.

The choice between either of the treatments needs to be individualized, taking into account the patient's clinical presentation, age, the surgical risk and their anatomy.^{19,22} In a patient with several comorbidities, with a high perioperative risk, in a context of elective repair and

with a suitable anatomy the endovascular repair is preferable. In patients that don't have a high surgical risk, open repair is still the gold standard^{10,18,24,30}.

Endovascular repair in emergent settings showed a lower limb salvage and higher reintervention rates in comparison with open repair at 30 days^{13,21,28}.

To justify the use of endovascular repair in emergent settings a study encompassing a larger number of patients and a longer follow up period is necessary.

The present review has limitations that warrant consideration. First, the selected studies exhibited important differences in terms of sample sizes. There was no homogeneity between studies regarding technique used and the indications to submit patients to endovascular vs. open repair. Patient characteristics were not equivalent to enable a fair comparison between both groups. Furthermore, each study had a different percentage of emergent cases, that are proved to be correlated with worse outcomes, and the data was presented as a total not indicating the percentage for elective vs. emergent setting. The open repair group tended to have a higher percentage of emergent cases in comparison with the endovascular group.

A multicenter randomized controlled trial with a longer follow-up period is, therefore, necessary to determine the roles of both strategies in the popliteal artery aneurysm repair^{32,36}.

Conclusion

Both open and endovascular repair represent valid and safe options for PAA repair.

Although endovascular' s repair increased popularity, open repair still remains the gold standard for the treatment of PAAs.

Endovascular repair seems an effective option in selected patients.

Further studies encompassing a longer follow-up period are needed to clarify the long-term results of endovascular repair.

REFERENCES

1. Dent TL, Lindenauer SM, Ernst CB, Fry WJ. Multiple arteriosclerotic arterial aneurysms. *Arch Surg* 1972; 105(2):338-344
2. Midy D, Berard X, Ferdani M, Alric P, Brizzi V, Ducasse E, et al. A retrospective multicenter study of endovascular treatment of popliteal artery aneurysm. *J Vasc Surg* 2010; 51(4):850-6.
3. Speziale F, Sirignano P, Menna D, Capoccia L, Mansour W, Serrao E, et al. Ten years' experience in endovascular repair of popliteal artery aneurysm using the Viabahn endoprosthesis: a report from two Italian vascular centers. *Ann Vasc Surg* 2015; 29(5):941-9.
4. Johnston KW, Rutherford RB, Tilson MD, Shah DM, Hollier L, Stanley JC. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, AdHoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. *J Vasc Surg* 1991; 13:452-8
5. Cervin A, Tjarnstrom J, Ravn H, Acosta S, Hultgren R, Welander M, et al. Treatment of Popliteal Aneurysm by Open and Endovascular Surgery: A Contemporary Study of 592 Procedures in Sweden. *Eur J Vasc Endovasc Surg* 2015; 50:342-50.
6. Wrede A, Wilberg F, Acosta S. Increasing the Elective Endovascular to Open Repair Ratio of Popliteal Artery Aneurysm. *Vasc Endovascular Surg* 2018; 52(2):115-123.
7. Trinidad-Hernandez M, Ricotta JJ 2nd, Gloviczki P, Kalra M, Oderich GS, Duncan AA, et al. Results of elective and emergency endovascular repairs of popliteal artery aneurysms. *J Vasc Surg* 2013; 57(5):1299-305.
8. Beseth BD, Moore WS. The posterior approach for repair of popliteal artery aneurysms. *J Vasc Surg* 2006; 43(5):940-4; discussion:944-5
9. Huang Y, Gloviczki P, Noel AA, Sullivan TM, Kalra M, Gullerud RE, et al. Early complications and long-term outcome after open surgical treatment of popliteal artery aneurysms: is exclusion with saphenous vein bypass still the gold standard? *J Vasc Surg* 2007; 45:706-13; discussion: 713-5.
10. Marin ML, Veith FJ, Panetta TF, Cynamon J, Bakal CW, Suggs WD, et al. Transfemoral endoluminal stented graft repair of a popliteal artery aneurysm. *J Vasc Surg* 1994;19(4):754e7

11. Jung E, Jim J, Rubin BG, Sanchez LA, Choi ET, Sicard GA, et al. Long-term outcome of endovascular popliteal artery aneurysm repair. *Ann Vasc Surg* 2010; 24(7):871-875.
12. Garg K, Rockman CB, Kim BJ, Jacobowitz GR, Maldonado TS, Adelman MA, et al. Outcome of endovascular repair of popliteal artery aneurysm using the Viabahn endoprosthesis. *J Vasc Surg* 2012;55: 1647-53.
13. Piazza M, Menegolo M, Ferrari A, Bonvini S, Ricotta JJ, Frigatti P, et al. Long-term outcomes and sac volume shrinkage after endovascular popliteal artery aneurysm repair. *Eur J Vasc Endovasc Surg* 2014; 48(2):161-8.
14. Saunders JH, Abisi S, Altaf N, Yong Y, MacSweeney ST, Whittaker S. Long-term outcome of endovascular repair of popliteal artery aneurysm presents a credible alternative to open surgery. *Cardiovasc Intervent Radiol* 2014;37(4): 914-9.
15. Golchehr B, Tielliu IF, Verhoeven EL, Mollenhoff C, Antonello M, Zeebregts CJ. Clinical Outcome of Isolated Popliteal Artery Aneurysms Treated with a Heparin-bonded Stent Graft. *Eur J Vasc Endovasc Surg* 2016;52: 99-104.
16. Maraglino C, Canu G, Ambrosi R, Briolini F, Gotti R, Cefali P, et al. Endovascular Treatment of Popliteal Artery Aneurysms: A Word of Caution after Long-Term Follow-up. *Ann Vasc Surg* 2017; 41:62-68.
17. Golchehr B, Zeebregts CJ, Reijnen MMPJ, Tielliu IFJ. Long-term outcome of endovascular popliteal artery aneurysm repair. *J Vasc Surg* 2018;67: 1797-1804.
18. Ardita V, Giaquinta A, Orrico M, Ronchey S, Veroux M, Mangialardi N, et al. Endovascular treatment of chronic occluded popliteal artery aneurysm: early and mid-term outcomes. *J Cardiovasc Surg (Torino)* 2018; 59: 405-11.
19. Guzzardi G, Natrella M, Del Sette B, Petullà M, Fanelli G, Porta C, et al. Endovascular repair of popliteal artery aneurysms: an Italian multicenter study. *Radiol Med* 2019; 124:79-85.
20. Zimmermann A, Schoenberger T, Saeckl J, Reeps C, Wendorff H, Kuehnl A, et al. Eligibility for endovascular technique and results of the surgical approach to popliteal artery aneurysms at a single center. *Ann Vasc Surg* 2010;24:342-8.
21. Dorweiler B, Gemechu A, Doemland M, Neufang A, Espinola-Klein C, Vahl CF. Durability of open popliteal artery aneurysm repair. *J Vasc Surg* 2014; 60(4):951-7.
22. Dorigo W, Pulli R, Alessi Innocenti A, Azas L, Fargion A, Chiti E, et al. A 33-year experience with surgical management of popliteal artery aneurysms. *J Vasc Surg* 2015; 62:1176-82.

23. Wagenhauser MU, Herma KB, Sagban TA, Dueppers P, Schelzig H, Duran M. Long-term results of open repair of popliteal artery aneurysm. *Ann Med Surg (Lond)* 2015; 4(1):58-63.
24. Pulli R, Dorigo W, Fargion A, Pratesi G, Innocenti AA, Angiletta D, et al. Comparison of early and midterm results of open and endovascular treatment of popliteal artery aneurysms. *Ann Vasc Surg* 2012; 26(6):809-18.
25. Pulli R, Dorigo W, Castelli P, Dorrucchi V, Ferilli F, De Blasis G, et al. A multicentric experience with open surgical repair and endovascular exclusion of popliteal artery aneurysms. *Eur J Vasc Endovasc Surg* 2013; 45:357-63.
26. Stone PA, Jagannath P, Thompson SN, Campbell JE, Mousa AY, Knackstedt K, et al. Evolving treatment of popliteal artery aneurysms. *J Vasc Surg* 2013;57(5): 1306-10.
27. Galiñanes EL, Dombrovskiy VY, Graham AM, Vogel TR. Endovascular versus open repair of popliteal artery aneurysms: outcomes in the US Medicare population. *Vasc Endovascular Surg* 2013; 47(04):267-73.
28. Huang Y, Gloviczki P, Oderich GS, Duncan AA, Kalra M, Fleming MD, et al. Outcomes of endovascular and contemporary open surgical repairs of popliteal artery aneurysm. *J Vasc Surg* 2014; 60(3):631-8.e2.
29. Ronchey S, Pecoraro F, Alberti V, Serrao E, Orrico M, Lachat M, et al. Popliteal Artery Aneurysm Repair in the Endovascular Era: Fourteen-Years Single Center Experience. *Medicine (Baltimore)* 2015; 94(30): e1130.
30. Leake AE, Avgerinos ED, Chaer RA, Singh MJ, Makaroun MS, Marone LK. Contemporary outcomes of open and endovascular popliteal artery aneurysm repair. *J Vasc Surg* 2016; 63:70-6.
31. Del Tatto B, Lejay A, Meteyer V, Roussin M, Georg Y, Thaveau F, et al. Open and Endovascular Repair of Popliteal Artery Aneurysms. *Ann Vasc Surg* 2018; 50:119-27.
32. Dorigo W, Fargion A, Masciello F, Piffaretti G, Pratesi G, Giacomelli E, et al. A Matched Case-Control Study on Open and Endovascular Treatment of Popliteal Artery Aneurysms. *Scand J Surg* 2018; 107:236-43.
33. Pulli R, Dorigo W, Troisi N, Innocenti AA, Pratesi G, Azas L, et al. Surgical management of popliteal artery aneurysms: which factors affect outcomes? *J Vasc Surg* 2006; 43(3):481-7

34. Serrano Hernando FJ, Martínez López I, Hernández Mateo MM, Hernando Rydings M, Sánchez Hervás L, Rial Horcajo R, et al. Comparison of popliteal artery aneurysm therapies. *J Vasc Surg* 2015; 61 (03): 655-661
35. Tielliu IF, Verhoeven EL, Prins TR, Post WJ, Hulsebos RG, van den Dungen JJ. Treatment of popliteal artery aneurysms with the Hemobahn stent-graft. *J Endovasc Ther* 2003; 10:111-6
36. Joshi D, James RL, Jones L: Endovascular versus open repair of asymptomatic popliteal artery aneurysm. *Cochrane Database Syst Rev* 2014;8:CD010149

NOTES

Conflicts of interest. The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Authors' contributions. Rita S. Sousa: manuscript design and conception, article writing, final approval of the manuscript. José Oliveira-Pinto: manuscript design and conception, article writing, final approval of the manuscript. Armando Mansilha: manuscript design and conception, final approval of the manuscript.

TABLES

Table I.— Patient characteristics

Article	Age(years)	Male	Smoker	Diabetes	Chronic kidney disease	Elective	Emergent	Stent type
Endovascular Repair								
Midy et al. (2010) ²	72+/-11	96%	82%	16%	-	89,5%: Asymptomatic-73.7% Symptomatic-15.8%	10,5%	Hemobahn/Viabahn-73.7% Wallgraft-24.5% Passager-1.8%
Jung et al. (2010) ¹¹	75+/-1.6	93%	45%	13%	-	100%: Asymptomatic-87% Symptomatic-13%	0%	Viabahn-100%
Garg et al. (2012) ¹²	74+/-9	90.5%	-	-	-	100% Asymptomatic-62% Symptomatic-38%	0%	Viabahn-100%
Trinidad-Hernandez et al. (2013) ⁷	81+/-5.9	96%	24%	16%	52%	61.2%: Asymptomatic-54.8% Symptomatic-6.5%	38.7%	Viabahn-100%

Piazza et al. (2014) ¹³	78.1+/-11	86%	64%	14%	21%	93% Asymptomatic- 58% Symptomatic- 42%	7%	Hemobahn-33% Viabahn-52% Viabahn+Advanta- 2% Heparin bonded Viabahn-13%
Saunders et al. (2014) ¹⁴	76 (62–88)	96%	-	-	-	68%	32%	Hemobahn-35.4% Viabahn-64.6%
Speziale et al. (2015) ³	73.6 +/-7.8	98.1%	66%	17%	20.7%	77.6%	22.6%	Viabahn-100%
Golchehr et al (2016) ¹⁵	71.2 +/-8.5	93%	40%	4%	37%	90.3% Asymptomatic- 78% Symptomatic- 12.3%	9.7%	Viabahn-100%
Maraglino et al. (2017) ¹⁶	Men-74 Women-77	93%	40%	9.2%	13.8%	66% Asymptomatic- 60% Symptomatic-6%	34%	Hemobahn/Viabahn- 100%
Golchehr et al. (2018) ¹⁷	68.1+/-9.4	97%	63%	14%	14%	94.3% Asymptomatic- 85.3% Symptomatic- 9.3%	5.3%	Hemobahn-52% Viabahn-48%
Ardita et al. (2018) ¹⁸	74.4+/-10.5	92%	44%	24%	24%	0%	100%	Viabahn and/or Advanta V12-40% Viabahn+BMS-60%
Guzzardi et	74.2 (42–92)	92%	63%	-	-	85.4%	14.6%	Viabahn-100%

al. (2019) ¹⁹						Asymptomatic- 64.6% Symptomatic- 20.8%		
Open Repair								
Zimmermann et al. (2010) ²⁰	71.5 (31-95)	95.7%	19.6%	17.4%	-	63% Asymptomatic- 63%	30.3%	-
Dorweiler et al. (2014) ²¹	67+/- 11	96.1%	48%	15%	14%	78% Asymptomatic- 57% Symptomatic- 21%	22%	-
Dorigo et al. (2015) ²²	68.5+/- 9.9	95%	77%	10%	-	71% Asymptomatic- 41.5% Symptomatic- 29.5%	29%	-
Wagenhauser et al. (2015) ²³	63.5 +/-10	93.3%	50%	-	-	100% Asymptomatic- 38.1% Symptomatic- 61.9%	0%	-
Both								

Endovascular	74	100%	71%	10%	-	80.5% Asymptomatic- 71% Symptomatic- 9.5%	19%	Hemobahn/Viabahn: 95.24% Cardiatis Multilayer 3D Stent:4.76%
Pulli et al. (2012) ²⁴								
Open repair	73.4	95.35%	81%	10%	-	68.3% Asymptomatic- 52% Symptomatic- 16.3%	32.6%	-
Endovascular	74.9 +/- 7.9	9.5%	70%	21%	-	91.8% Asymptomatic- 61.2% Symptomatic- 30.6%	8.2%	Hemobahn/Viabahn- 100%
Pulli et al. (2013) ²⁵								
Open repair	70 +/-8.9	7.5%	55%	20.5%	-	77% Asymptomatic- 35.5% Symptomatic- 41.5%	23%	-
Endovascular	76 +/- 9.80	95%	70%	-	-	70.8% Asymptomatic- 54.1% Symptomatic- 16.7%	29%	Viabahn-100%
Stone et al. (2013) ²⁶								

Open repair	65.96+/-12.56	100%	69.2%	-	-	65% Asymptomatic- 44.4% Symptomatic- 20.6%	36.5%	-
Endovascular	77.9+/-7.01	90.9%	-	-	-	-	-	-
Galinanes et al.(2013) ²⁷								
Open repair	76.3 +/-6.20	95%	-	-	-	-	-	-
Endovascular	81 +/- 6.5	100%	-	-	3%	76.1% Asymptomatic- 69% Symptomatic- 7.1%	23.8%	Viabahn-100%
Huang et al. (2014) ²⁸								
Open repair	71 +/- 9.6	99%	-	-	3%	86.6% Asymptomatic- 52% Symptomatic- 34.6%	13%	-

Endovascular	Acute ischaemia: 70 (46-88) Elective symptomatic: 78 (63-88) Elective asymptomatic: 78 (63-88)	93.7%	77.9%	15.8%	-	71.6% Asymptomatic- 57.9% Symptomatic- 13.7%	28.4%	-
Cervin et al. (2015) ⁵								
Open repair	Acute ischaemia: 69 (42-102) Elective symptomatic: 68 (46-93) Elective asymptomatic: 68 (50-90)	96.2%	81%	14%	-	70.8% Asymptomatic- 51.8% Symptomatic- 19%	29.2%	-
Endovascular	71+/-6	-	56%	28%	36%	84% Asymptomatic- 76% Symptomatic- 8%	16%	Viabahn-100%
Ronchey et al. (2015) ²⁹								
Open Repair	Group B: 66+/-10 Group C: 68+/-7	-	57.1%	31%	11.9%	76.2% Asymptomatic- 59.5% Symptomatic- 16.7%	23.8%	-
Endovascular	72.7	96.7%	31.6%	22%	-	88.2%	11.8%	Viabahn-100%

Leake et al. (2016) ³⁰								
Open repair	70.5	95.8%	43.5%	25%	-	57%	43%	-
Endovascular								
Wrede et al. (2017) ⁶	69 (56-87)	92.6%	88.9%	25.9%	19.2%	40.9%	35.3%	Viabahn-100%
Open repair	66 (48-81)	100%	82.1%	10.3%	17.9%	59.1%		-
Endovascular								
Del Tatto et al. (2018) ³¹	70.4 (53-86)	92.3%	59%	5.1%	7.6%	90% Asymptomatic- 84% Symptomatic-6%	10%	Viabahn-100%
Open repair	69.4 (48-89)	95.4%	32.2%	2.3%	8%	70.9% Asymptomatic- 60.2% Symptomatic- 10.7%	29%	-
Endovascular								
Dorigo et al. (2018) ³²	74.1 +/-7.8	100%	87.5%	7%	-	75% Asymptomatic- 69.6% Symptomatic - 5.4%	25%	Viabahn/Hemobahn: 98.2% Cardiatis Multilayer 3D Stent:1.8%
						83.9%		

Open repair	74.1 +/- 7.8	98.2%	77%	12.5%	-	Asymptomatic- 66% Symptomatic- 17.9%	16%	-
-------------	--------------	-------	-----	-------	---	---	-----	---

Group B: great saphenous vein bypass; Group C: prosthetic graft bypass

Table II.— Study characteristics

Article	Patients	PAAs	Perioperative deaths (<30days)	Mean follow-up(months)
Endovascular:12 articles				
Midy et al. (2010)²	50	57	0	36+/-19,4
Jung et al. (2010)¹¹	13	15	0	54(42-70)
Garg et al. (2012)¹²	21	26	0	22+/-17
Trinidad - Hernandez et al.(2013)⁷	25	31	Overall:2/31(6,4%) Elective:0 Emergent:2/12(16,7%)	21,3 (1-75)
Piazza et al. (2014)¹³	42	46	0	56+/-21
Saunders et al. (2014)¹⁴	26	34	0	40 (4–86)
Speziale et al. (2015)³	53	53	0	37.4 +/- 29.3
Golchehr et al. (2016)¹⁵	70	72	0	13 (0-63)
Maraglino et al. (2017)¹⁶	57	65	0	35 +/- 25
Golchehr et al. (2018)¹⁷	64	75	0	68 (2-187)
Ardita et al. (2018)¹⁸	25	30	0	21.8+/-15.8
Guzzardi et al. (2019)¹⁹	48	48	0	24.5 (6–72)
Open Surgery:4 articles				
Zimmermann et al.	46	56	2/46(4,3%)	20.5 (0.73)

(2010)²⁰				
Dorweiler et al. (2014)²¹	154	206	3/154(2%)	137 (1-185)
Dorigo et al. (2015)²²	196	234	2/196(1%)	62 (1-312)
Wagenhauser et al.(2015)²³	30	42	0	38.7+/- 29.2
Both:11 articles				
Pulli et al. (2012)²⁴	59	64: 43OR 21ER	OR:0 ER:1/21(4,7%)	22.5(1-60).
Pulli et al. (2013)²⁵	249	312: 178OR 134ER	OR:0 ER:2/134(1,5%)	OR: 27 (1-156) ER: 35(1-124)
Stone et al. (2013)²⁶	72	88: 64OR 24ER	OR:1/63(1,6%) ER:0	OR: 29.2 (0-116) ER: 22.4 (0-105)
Galinas et al. (2013)²⁷	2962	2962: 2413OR 549ER	NR	NR
Huang et al. (2014)²⁸	120	149: 107OR 42ER	OR:1/107(0,9%) ER:2/42(4,7%)	OR:45.6 (1-100.8) ER: 31.2 (1-78)
Cervin et al. (2015)⁵	499	592 473OR 95ER	OR:2/473(0,42%) ER:1/95(1%)	12
Ronchey et al. (2015)²⁹	67	67: 42OR 25ER	0	49(1-145)
Leake et al. (2016)³⁰	156	186: 110OR 76ER	OR:2/110(1,8%) ER:0	OR: 34.9+/- 28.6 ER: 28.3+/- 25.8
Wrede et al. (2017)⁶	87	102: 39OR 27ER 36AR	0	OR:39 ER:24

Del Tatto et al. (2018)³¹	126	153: 103OR 50ER	0	45.6
Dorigo et al. (2018)³²	108 matched	309 250OR 59ER (matched 56OR 56ER)	OR:0 ER:1/56(1,8%)	OR: 71.5 +/- 10.4 ER: 36.4 +/- 3.4

ER: Endovascular Repair; OR: Open Repair; PAAs: Popliteal artery aneurysms; AR: Acute repair

Table III.— Mid-term outcomes

Article	Procedure	Technical success rate	Reintervention	Limb Salvage
Midy et al. (2010)²	endovascular	56/57(98,2%)	36+/- 19.4 months: 14/57(24,56%)	36+/- 19.4 months:55/57(96,5%)
Jung et al. (2010)¹¹	endovascular	15/15(100%)	54 months(42-70):2/12(16,7%)	54months(42-70): 15/15 (100%)
Garg et al. (2012)¹²	endovascular	25/26(96%)	NS	22+/- 17 months: 26/26(100%)
Trinidad - Hernandez et al. (2013)⁷	endovascular	30 /31(97%)	21,3months (1-75): Overall:9/31(29%) Elective:6/19(31,6%) Emergent: 3/12(25%)	1year:30/31(97%)
Piazza et al. (2014)¹³	endovascular	45/46 (98%)	NS	5 years :45/46(98%)
Saunders et al. (2014)¹⁴	endovascular	34/34 (100%)	1year: 4/34(12%)	1year:32/34(94,1%) 3years:18/18(100%) 5years:5/5(100%)
Speziale et al. (2015)³	endovascular	53/53(100%)	37.4months+/-29.3 :10/53(18,9%)	37.4months+/-29.3: 53/53(100%)
Golchehr et al. (2016)¹⁵	endovascular	72/72 (100%)	NS	13 months (0-63): 72/72(100%)
Maraglino et al. (2017)¹⁶	endovascular	64/65(98,5%)	NS	5years:54/65(83%)
Golchehr				

et al. (2018)¹⁷	endovascular	NS	14months (1-47):12/75 (16%)	68 months (2-187) = 75/75(100%)
Ardita et al. (2018)¹⁸	endovascular	30/30(100%)	1 year:6 /30(21%) 3 year:8 /30(26,7%)	1 year:30/30(100%) 3 year: 30/30(100%)
Guzzardi et al. (2019)¹⁹	endovascular	48/48(100%)	24.5 months (6-72): 3/48(6,25%)	24.5 months (6-72) =48/48(100%)
Zimmermann et al. (2010)²⁰	open surgery	54/54(100%)	20.5 months (0.73):5/31(16,1%)	20.5 months (0.73):31/31(100%)
Dorweiler et al. (2014)²¹	open surgery	200/206(97%)	5years:32/206(15,7%) 10years:62/206(30,2%)	Overall:5 and 10 years-200/206(97%); emergent:5 and 10 years-41/45(91,1%); elective:5 and 10 years-159/161(98,6%)
Dorigo et al. (2015)²²	open surgery	NS	5years:55/210(26,2%) 10years:77/210(36,5%) 13years:80/210(38%)	5years:191/210(91,2%) 10years:180/210(86%) 13years:180/210(86%)
Wagenhauser et al. (2015)²³	Open surgery	NS	NS	30days: Overall:(100+86,7) /2 (93,3%) Symptomatic: -/- (86,7%) Asymptomatic:16/16 (100%)
Pulli et al. (2012)²⁴	open surgery	NS	2years:9/43 (21%)	22,5months (1-60):38/41(92,7%)
	endovascular	21/21(100%)	2years: - /- (38,5%)	22,5months (1-60):19/20(95%)
	open surgery	NS	1year:22/168(13%) 2years:-/-(13,9%) 4years:-/-(27,5%)	1years: -/-(94,3%) 2years:-/-(92,6%) 4years:-/-(89,7%)
Pulli et al. (2013)²⁵	endovascular	134/134 (100%)	1year:-/-(19,4%) 2years:-/-(22,8%) 4years:-/-(25%)	1year:-/-(98,1%) 2years:-/-(96,9%) 4years:-/-(96,9%)
Stone et al. (2013)²⁶	open surgery	50/63(79%)	NS	29,2months:58/64 (90,6%)
	endovascular	20/24(83.3%)	2years:2/24 (8,3%)	22,4months:24/24

				(100%)
Galinanés et al. (2013)²⁷	open surgery	NS	30days:51/2413(2,11%) 90days:110/2413(4,55%)	NS
	endovascular	NS	30days:41/549(7,42%) 90days:65/549(11,84%)	NS
Huang et al. (2014)²⁸	open surgery	NS	30days Overall:4/107(4%) Elective:1/93(1%) Emergent:3/14(21,4%) 3years Overall:18/107(16,8%) Elective:12/93(12%) Emergent:6/14(43%)	3years Overall:106/107(99%) Elective:92/93(99%) Emergent:14/14(100%)
	endovascular	41/42(98%)	30days Overall:5/42(12%) Elective:1/32(3%) Emergent:4/10(40%) 3 years Overall:14/42(33,3%) Elective:9/32(28%) Emergent:5/10(52%)	3years Overall:42/42(100%) Elective:32/32(100%) Emergent:10/10(100%)
Cervin et al. (2015)⁵	open surgery	NS	NS	Acute Ischaemia: 1year-109/117(93,2%) Symptomatic: 1year-74/81(91,4%) Asymptomatic: 1year-218/220(99%) Overall: 1year-401/418(95,9%)
	endovascular	NS	NS	Acute Ischaemia: 1year-19/23(82,6%) Symptomatic: 1year-9/9(100%) Asymptomatic: 1year-49/50(98%) Overall: 1year-77/82(93,9%)
Ronchey et al. (2015)²⁹	Open surgery-GSV bypass	28/28 (100%)	49 months (1-145): 5/28(17,8%) 5years:-/-(16%)	49months (1-145): 27/28(96,4%)
	Open surgery-Prosthetic garft bypass	14/14 (100%)	49months (1-145): 3/14(21,4%) 5years:-/-(30%)	49 months(1-145): 14/14 (100%)

	endovascular	25/25 (100%)	49 months (1-145): 4/25(16%) 5years:-/-(38%)	49months(1-145): 25/25(100%)
Leake et al. (2016)³⁰	open surgery	110/110(100%)	34.9months+/- 28.6 :4/110 (3,6%)	34.9months+/- 28.6 :106/110(96,3%)
	endovascular	76/76(100%)	28.3months+/- 25.8 :7/76(9,2%)	28.3months+/- 25.8 :75/76(98,7%)
Wrede et al. (2017)⁶	open surgery	NS	1year:5/39(12,8%)	1year:36/36(100%)
	endovascular	NS	1year:1/27(3,7%)	1year:16/19(84,2%)
Del Tatto et al. (2018)³¹	open surgery	103/103(100%)	NS	1year:-/-(94,5%) 3years:-/-(94,5%) 5years:-/-(89,5%)
	endovascular	50/50(100%)	NS	1year:-/-(97,7%) 3years:-/-(88,9%) 5years:-/-(64,7%)
Dorigo et al. (2018)³²	open surgery	NS	5years:-/-(24%)	5years:-/-(86,4%)
	endovascular	56/56(100%)	5years:-/-(34,5%)	5years:-/-(94%)

NS: Not stated; GSV: great saphenous vein




Figure 1.— Flowchart summarizing literature screening process.

INTERNATIONAL ANGIOLOGY

A Journal on Angiology

Official Journal of the **International Union of Angiology, Latin American Venous Forum, UEMS Multidisciplinary Joint Committee on Phlebology, European Board of Phlebology, Central European Vascular Forum, European Venous Forum**

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus

Impact Factor 1,279

Frequency: Bi-Monthly

pISSN 0392-9590

eISSN 1827-1839

INSTRUCTIONS TO AUTHORS

The journal **International Angiology** publishes scientific papers on angiology. Manuscripts may be submitted in the form of editorials, original articles, review articles, special articles, letters to the Editor and guidelines.

Manuscripts are expected to comply with the instructions to authors which conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Editors by the International Committee of Medical Journal Editors (<http://www.icmje.org>).

Articles not conforming to international standards will not be considered for acceptance.

Submission of manuscripts

Papers should be submitted directly to the online Editorial Office at the Edizioni Minerva Medica website: <http://www.minervamedicaonlinesubmission.it>

Authors are requested to choose a corresponding author delegated to communicate with the journal during the manuscript submission, peer review and publication process. Although for technical and organizational reasons the corresponding author has primary responsibility for correspondence with the journal, copies of the most significant correspondence will be sent to all listed authors.

Duplicate or multiple publication

Submission of the manuscript means that the paper is original and has not yet been totally or partially published, is not currently under evaluation elsewhere, and, if accepted, will not be published elsewhere either wholly or in part.

Splitting the data concerning one study in more than one publication could be acceptable if authors justify the choice with good reasons both in the cover letter and in the manuscript. Authors should state what new scientific contribution is contained in their manuscript compared to any previously published article derived from the same study. Relevant previously published articles should be included in the cover letter of the currently submitted article.

Permissions to reproduce previously published material

Material (such as illustrations) taken from other publications must be accompanied by the publisher's permission.

Copyright

The Authors agree to transfer the ownership of copyright to International Angiology in the event the manuscript is published.

Ethics committee approval

All articles dealing with original human or animal data must include a statement on ethics approval at the beginning of the methods section, clearly indicating that the study has been approved by the ethics committee. This paragraph must contain the following information: the identification details of the ethics committee; the name of the chairperson of the ethics committee; the protocol number that was attributed by the ethics committee and the date of approval by the ethics committee.

The journal adheres to the principles set forth in the Helsinki Declaration

(<http://www.wma.net/en/30publications/10policies/b3/index.html>) and states that all reported research concerning human beings should be conducted in accordance with such principles. The journal also adheres to the International Association of Veterinary Editors' Consensus Author Guidelines on Animal Ethics and Welfare (<http://www.veteditors.org/consensus-author-guidelines-on-animal-ethics-and-welfare-for-editors>) and requires that all research on animals be conducted in accordance with these principles.

Patient consent

Authors should include at the beginning of the methods section of their manuscript a statement clearly indicating that patients have given their informed consent for participation in the research study.

Every precaution must be taken to protect the privacy of patients. Authors should obtain permission from the patients for the publication of photographs or other material that might identify them. If necessary a copy of such permission may be request.

Conflicts of interest

Authors must disclose possible conflicts of interest including financial agreements or consultant relationships with organizations involved in the research. All conflicts of interest must be declared both in the authors' statement form and in the manuscript file. If there is no conflict of interest, this should also be explicitly stated as none

declared. All sources of funding should be acknowledged in the manuscript.

Authorship and contributorship

All persons and organizations that have participated to the study must be listed in the byline of the article (authors) or in the notes (contributors). The manuscript should be approved by all co-authors, if any, as well as, tacitly or explicitly, by the responsible authorities of the institution where the work was carried out. Authors and contributors must meet the criteria for authorship and contributorship established by the Uniform Requirements for Manuscripts Submitted to Biomedical Editors by the International Committee of Medical Journal Editors (<http://www.icmje.org>).

Authors' statement

Papers must be accompanied by the authors' statement

(https://www.minervamedica.it/authors_statement/international-angiology/authors_statement.doc)

relative to copyright, originality, authorship, ethics and conflicts of interest, signed by all authors.

Disclaimer

The Publisher, Editors, and Editorial Board cannot be held responsible for the opinions and contents of publications contained in this journal.

The authors implicitly agree to their paper being peer-reviewed. All manuscripts will be reviewed by Editorial Board members who reserve the right to reject the manuscript without entering the review process in the case that the topic, the format or ethical aspects are inappropriate. Once accepted, all manuscripts are subjected to copy editing. If modifications to the manuscript are requested, the corresponding author should send to the online Editorial Office the revised manuscript under two separate files, one file containing the revised clean version and another containing both a letter with point-by-point responses to the reviewers' comments and the revised version with corrections highlighted.

Correction of proofs should be limited to typographical errors. Substantial changes in content (changes of title and authorship, new results and corrected values, changes in figures and tables) are subject to editorial review. Changes that do not conform to the journal's style are not accepted. Corrected proofs must be sent back within 3 working days to the online Editorial Office of International Angiology. In case of delay, the editorial staff of the journal may correct the proofs on the basis of the original manuscript.

Publication of manuscripts is free of charge. IUA members will receive 25 reprints free of charge. Colour figures, linguistic revision, and excessive alterations to proofs will be charged to the authors. Authors will receive instructions on how to order reprints and a copy of the manuscript in PDF.

For further information about publication terms please contact the Editorial Office of International Angiology, Edizioni Minerva Medica, Corso Bramante 83-85, 10126 Torino, Italy - Phone +39-011-678282 - Fax +39-011-674502

E-mail: journals6.dept@minervamedica.it.

ARTICLE TYPES

Instructions for the most frequent types of articles submitted to the journal.

Editorials. Commissioned by the Editor in Chief or the Managing Editor, editorials deal with a subject of topical interest about which the author expresses his/her personal opinion. The text must not be subdivided. No more than 1000 words (3 typed, double-spaced pages) and up to 15 references will be accepted.

Original articles. These should be original contributions to the subject. The text should be 3000-5500 words (8 to 16 typed, double-spaced pages) not including references, tables, figures. No more than 50 references will be accepted. The article must be subdivided into the following sections: introduction, materials (patients) and methods, results, discussion, conclusions. The introduction should describe the theoretical background, the aim of the study and the hypothesis to be tested. The materials and methods section should describe in a logical sequence how the study was designed and carried out, how the data were analyzed (what hypothesis was tested, what type of study was carried out, how randomization was done, how the subjects were recruited and chosen, provide accurate details of the main features of treatment, of the materials used, of drug dosages, of unusual equipments, of the statistical method ...). In the results section the answers to the questions posed in the introduction should be given. The results should be reported fully, clearly and concisely supported, if necessary, by figures, graphs and tables. The discussion section should sum up the main results, critically analyze the methods used, compare the results obtained with other published data and discuss the implications of the results. The conclusions should briefly sum up the significance of the study and its future implications. For randomised controlled trials it is suggested to the authors to conform the structure of their paper to the checklist requirements of the following guidelines reported by the CONSORT statement: <http://www.consort-statement.org>.

Review articles. These articles are commissioned by the Editor in Chief or the Managing Editor. They should discuss a topic of current interest, outline current knowledge of the subject, analyze different opinions regarding the problem discussed, be up-to-date on the latest data in the literature. Systematic reviews and meta-analyses must be subdivided into the following sections: introduction, evidence acquisition, evidence synthesis, conclusions. For systematic reviews and meta-analyses it is suggested to the authors to conform the structure of their paper to the checklist requirements of the following guidelines reported by the PRISMA statement: <http://www.prisma-statement.org>. The text should be 6000-12000 words (17 to 34 typed, double-spaced pages) not including references, tables, figures. No more than 100 references will be accepted.

Special articles. These are articles on the history of medicine, health care delivery, ethics, economic policy and law concerning angiology. The text should be 3000-7000 words (8 to 20 typed, double-spaced pages) not including references, tables, figures. No more than 50 references will be accepted.

Letters to the Editor. These may refer to articles already published in the journal or to particularly interesting observations or scientific data that the authors wish to present to readers in a concise form. The text must not be subdivided and should be 500-1000 words (1 to 3 typed, double-spaced pages) not including references, tables, figures. No more than 5 references will be accepted.

Guidelines and Consensus. These are documents drawn up by special committees or authoritative sources. The number of figures and tables should be appropriate for the type and length of the paper.

PREPARATION OF MANUSCRIPTS

Text file

Manuscripts must be drafted according to the template for each type of paper ([editorial](#), [original article](#), [review](#), [special article](#), [letter to the Editor](#), [guidelines and consensus](#)).

The formats accepted are Word (.DOC and .DOCX) and RTF. The text file must contain title, authors' details, abstract, key words, text, references, notes, tables and titles of tables and figures. Figures should be submitted as separate files. The file should not contain active hyperlinks.

Title and authors' details

Short title, with no abbreviations. First name in full, middle name's initial, surname of the authors. Collective name, if any, as last author. Corresponding author marked with an asterisk. Affiliation (section, department and institution) of each author. Name, address, e-mail of the corresponding author.

Abstract and key words

Articles should include an abstract of between 200 and 250 words. For original articles, the abstract should be structured as follows: background (what is already known about the subject and what the study intends to examine), methods (experimental design, patients and interventions), results (what was found), conclusions (meaning of the study). For systematic reviews and meta-analyses, the abstract should be structured as follows: introduction, evidence acquisition, evidence synthesis, conclusions. Key words should refer to the terms from Medical Subject Headings (MeSH) of MEDLINE/PubMed. No abstracts are required for editorials or letters to the Editor.

Text

Identify methodologies, equipment (give name and address of manufacturer in brackets) and procedures in sufficient detail to allow other researchers to reproduce results. Specify well-known methods including statistical procedures; mention and provide a brief description of published methods which are not yet well known; describe new or modified methods at length; justify their use and evaluate their limits. For each drug generic name, dosage and administration routes should be given. Brand names for drugs should be given in brackets. Units of measurement, symbols and abbreviations must conform to international standards. Measurements of length, height, weight and volume should be given in metric units (meter, kilogram, liter) or their decimal multiples. Temperatures must be expressed in degrees Celsius. Blood pressure must be expressed in millimeters of mercury. All clinical chemistry measurements should be expressed in metric units using the International System of Units (SI). The use of unusual symbols or abbreviations is strongly discouraged. The first time an abbreviation appears in the text, it should be preceded by the words for which it stands.

References

It is expected that all cited references will have been read by the authors. The references must contain only the authors cited in the text, be numbered in Arabic numerals and consecutively as they are cited. Bibliographical entries in the text should be quoted using superscripted Arabic numerals. References must be set out in the standard format approved by the International Committee of Medical Journal Editors (<http://www.icmje.org>).

Journals

Each entry must specify the author's surname and initials (list all authors when there are six or fewer; when there are seven or more, list only the first six and then "*et al.*"), the article's original title, the name of the Journal (according to the abbreviations used by MEDLINE/PubMed), the year of publication, the volume number and the number of the first and last pages. When citing references, please follow the rules for international standard punctuation carefully.

Examples:

- Standard article.

Sutherland DE, Simmons RL, Howard RJ. Intracapsular technique of transplant nephrectomy. *Surg Gynecol Obstet* 1978;146:951-2.

- Organization as author

International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. *Ann Int Med* 1988;108:258-65.

- Issue with supplement

Payne DK, Sullivan MD, Massie MJ. Women's psychological reactions to breast cancer. *Semin Oncol* 1996;23(1 Suppl 2):89-97.

Books and monographs

For occasional publications, the names of authors, title, edition, place, publisher and year of publication must be given.

Examples:

- Books by one or more authors

Rossi G. *Manual of Otorhinolaryngology*. Turin: Edizioni Minerva Medica; 1987.

- Chapter from book

De Meester TR. Gastroesophageal reflux disease. In: Moody FG, Carey LC, Scott Jones R, Ketly KA, Nahrwold

DL, Skinner DB, editors. Surgical treatment of digestive diseases. Chicago: Year Book Medical Publishers; 1986. p. 132-58.

- Congress proceedings

Kimura J, Shibasaki H, editors. Recent advances in clinical neurophysiology. Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology; 1995 Oct 15-19; Kyoto, Japan. Amsterdam: Elsevier; 1996.

Electronic material

- Standard journal article on the Internet

Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. *Ann Intern Med* [Internet]. 2006 Jul 4 [cited 2007 Jan 4];145(1):62-9. Available from:

<http://www.annals.org/cgi/reprint/145/1/62.pdf>

- Standard citation to a book on CD-ROM or DVD

Kacmarek RM. Advanced respiratory care [CD-ROM]. Version 3.0. Philadelphia: Lippincott Williams & Wilkins; ©2000. 1 CD-ROM: sound, color, 4 3/4 in.

- Standard citation to a homepage

AMA: helping doctors help patients [Internet]. Chicago: American Medical Association; ©1995-2007 [cited 2007 Feb 22]. Available from: <http://www.ama-assn.org/>.

Footnotes and endnotes of Word must not be used in the preparation of references.

References first cited in a table or figure legend should be numbered so that they will be in sequence with references cited in the text taking into consideration the point where the table or figure is first mentioned.

Therefore, those references should not be listed at the end of the reference section but consecutively as they are cited.

Notes

Conflicts of interest; mention of any funding, research contracts; authors' contribution statement; list of the members of the collective name (author's name in full, middle name's initial in capital letters and surname, with relevant affiliation); contributors' names; dates of any congress where the paper has already been presented; acknowledgements.

Tables

Tables should be submitted in the text file. Each table should be created with the Table menu of Microsoft Word table editor, by selecting the number of rows and columns needed. Tabulations are not allowed. Each table must be numbered in Roman numerals and accompanied by the relevant title. Each table must include heading, body and notes, if needed, at the foot of the table. Tables should be referenced in the text sequentially.

Figures

Each figure should be submitted as a separate file. Formats accepted: JPEG set at 300 dpi resolution preferred; other formats accepted are TIFF and PDF (high quality). Figures should be numbered in Arabic numerals and accompanied by the relevant title. Titles of figures should be repeated also in the text file. Figure should be referenced in the text sequentially.

Reproductions should be limited to the part that is essential to the paper.

Histological photographs should always be accompanied by the magnification ratio and the staining method.

If figures are in color, it should always be specified whether color or black and white reproduction is required.

Supplementary Digital Material

Authors may submit supplementary material to support and enhance their article's text to be published in the online edition only. Supplementary material should be submitted online during the submission process and may include the following types of content: text files, tables, figures, audios and videos. Authors are requested to submit as supplementary material tables that are too long to fit on a single printed page of the journal and any appendices.

One or more files of supplementary material may be attached to the article. Such files must be submitted separately and cited in consecutive order in the text. There are no restrictions on the content of a file (it may include a text and a table, a single table, a figure and a table, two figures, a video, etc.).

Each in-text citation of supplementary material should be clearly labeled as "Supplementary Digital Material" followed by the relevant number and the description of the material submitted (Supplementary Digital Material 1: Supplementary Text File, Supplementary Figure 1, Supplementary Table I and Supplementary Table II online content only). Audio and video citations should also include the length and size of the file (Supplementary Digital Material 2: Supplementary Video 1, online content only, 5 minutes, 10MB). Text files, figures and tables of supplementary materials should be accompanied by the relevant title.

Formats accepted for text files and tables: Word (.DOC and .DOCX) and RTF; formats accepted for figures: JPEG set at 300 dpi resolution preferred; other formats accepted are TIFF and PDF (high quality); formats accepted for audio files: MP3, WAV; formats accepted for video files: MP4, AVI, WMV. To ensure a quality experience, it is suggested that authors submit supplementary audios and videos no larger than 10 MB each. If accepted, supplementary material will be published as submitted and will not be checked or corrected.

INSTRUCTIONS FOR MANUSCRIPT FORMATTING

- Insert the text in the relevant sections according to the instructions you will find in the boxes and then remove all boxes (including this one)
- Use the same font all over the manuscript: Times New Roman 12, 1.5 line spacing
- Do not insert line numbers, page numbers, headings or footnotes
- Tables and figures should not be included in the manuscript file – please upload them as separate files from the text at the online submission system
- Insert references as plain text without using footnotes and endnotes of Word
- Active hyperlinks should not be included in the text or in the references.

TITLE

Short title, with no abbreviations, in lowercase upright letters.

Lorem ipsum dolor sit amet, consectetur adipiscing elit

AUTHORS

Author's name in full, middle name's initial in capital letters and surname. Names must be separated by a comma. Superscribe the Arabic numeral referring to the author's institution. Numbering should begin with the name of the first author. Please mark the corresponding author with an asterisk. A collective name can be added as last author.

INDIVIDUAL AUTHORS

All authors are individual authors.

Name M. SURNAME¹ *, Name M. SURNAME², Name M. SURNAME³

COLLECTIVE AUTHOR – CASE 1

All individual authors (limited number) are part of the collective author (group, society) on behalf of which they have prepared the manuscript. All members of the collective author, including the manuscript's authors, may be listed at the end of the manuscript under the Group Name (see Notes section at the end of the template) and will appear in PubMed as Collaborators.

CASE 1

Name M. SURNAME¹ *, Name M. SURNAME², Name M. SURNAME³ on behalf of/ for Group Name[‡]

[‡]Members are listed at the end of the paper (optional)

COLLECTIVE AUTHOR – CASE 2

Individual authors are followed by a collective author (group, society) which some individual authors may also be part of. All members of the collective author may be listed at the end of the manuscript under the Group Name. Authors and contributors can be specified (see Notes section at the end of the template). Contributors who are part of the collective author will appear in PubMed as Collaborators.

CASE 2

Name M. SURNAME¹ *, Name M. SURNAME², Name M. SURNAME³, Group Name[‡]

[‡]Members are listed at the end of the paper (optional)

COLLECTIVE AUTHOR – CASE 3

Individual authors are followed by a collective author (group, society) they are not part of. All members of the collective author may be listed at the end of the manuscript under the Group Name. Authors and contributors can be specified (see Notes section at the end of the template). Individual authors who are part of the collective author will appear in PubMed under the authors' byline before the name of the collective author, whereas contributors who are part of the collective author will appear as Collaborators. If authors and contributors are not specified, all members of the collective author will be listed in PubMed as Collaborators.

CASE 3

Name M. SURNAME¹ *, Name M. SURNAME², Name M. SURNAME³, Group Name[‡]

[‡]Members are listed at the end of the paper (optional)

AFFILIATIONS

Every entry must be accompanied by the superscribed Arabic numeral of the author in question and must be complete (Section, Department, Institution...). Affiliations should be separated by a semicolon without any line break.

¹Section, Department, Institution, Town, Country; ²Section, Department, Institution, Town, Country; ³ Section, Department, Institution, Town, Country

**CORRESPONDING
AUTHOR**

Name, address, e-mail of the corresponding author preceded by
“*Corresponding author:”

*Corresponding author: Name M. Surname, Section, Department, Institution, Address, Zip Code, Town, Country. E-mail:

ABSTRACT

ABSTRACT

Articles should include an abstract of between 200 and 250 words. For systematic reviews and meta-analyses, the abstract should be structured as follows: introduction, evidence acquisition, evidence synthesis, conclusions. Insert the text in the related sections; typeset subtitles in upright non-italicized uppercase text followed by a colon.

INTRODUCTION:

EVIDENCE ACQUISITION:

EVIDENCE SYNTHESIS:

CONCLUSIONS:

KEY WORDS

Key words should refer to the terms from Medical Subject Headings (MeSH) of the Index Medicus and should include at least three items.

Key words:

TEXT

Review articles. These articles are commissioned by the Editor in Chief or the Managing Editor. They should discuss a topic of current interest, outline current knowledge of the subject, analyze different opinions regarding the problem discussed, be up-to-date on the latest data in the literature. Systematic reviews and meta-analyses must be subdivided into the following sections: introduction, evidence acquisition, evidence synthesis, conclusions. For systematic reviews and meta-analyses it is suggested to the authors to follow the guidelines reported by the PRISMA statement (<http://www.prisma-statement.org>). The text should be 6000-12000 words (17 to 34 typed, double-spaced pages) not including references, tables, figures. No more than 100 references will be accepted.

Insert the text here.

REFERENCES

It is expected that all cited references will have been read by the authors. The references must contain only the authors cited in the text, be numbered in Arabic numerals and consecutively as they are cited. Bibliographical entries in the text should be quoted using superscripted Arabic numerals. References must be set out in the standard format approved by the International Committee of Medical Journal Editors (www.icmje.org).

JOURNALS

Each entry must specify the author's surname and initials (list all authors when there are six or fewer; when there are seven or more, list only the first six and then "et al."), the article's original title, the name of the Journal (according to the abbreviations used by MEDLINE/PubMed), the year of publication, the volume number and the number of the first and last pages. When citing references, please follow the rules for international standard punctuation carefully.

Examples:

- Standard article.

Sutherland DE, Simmons RL, Howard RJ. Intracapsular technique of transplant nephrectomy. *Surg Gynecol Obstet* 1978;146:951-2.

- Organization as author

International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. *Ann Int Med* 1988;108:258-65.

- Issue with supplement

Payne DK, Sullivan MD, Massie MJ. Women's psychological reactions to breast cancer. *Semin Oncol* 1996;23(1 Suppl 2):89-97.

BOOKS AND MONOGRAPHS

For occasional publications, the names of authors, title, edition, place, publisher and year of publication must be given.

Examples:

- Books by one or more authors

Rossi G. *Manual of Otorhinolaryngology*. Turin: Edizioni Minerva Medica; 1987.

- Chapter from book

De Meester TR. Gastroesophageal reflux disease. In: Moody FG, Carey LC, Scott Jones R, Ketly KA, Nahrwold DL, Skinner DB, editors. *Surgical treatment of digestive diseases*. Chicago: Year Book Medical Publishers; 1986. p. 132-58.

- Congress proceedings

Kimura J, Shibasaki H, editors. *Recent advances in clinical neurophysiology. Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology*; 1995 Oct 15-19; Kyoto, Japan. Amsterdam: Elsevier; 1996.

ELECTRONIC MATERIAL

- Standard journal article on the Internet

Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. *Ann Intern Med* [Internet]. 2006 Jul 4 [cited 2007 Jan 4];145(1):62-9. Available from: <http://www.annals.org/cgi/reprint/145/1/62.pdf>

- Standard citation to a book on CD-ROM or DVD

Kacmarek RM. *Advanced respiratory care [CD-ROM]*. Version 3.0. Philadelphia: Lippincott Williams & Wilkins; ©2000. 1 CD-ROM: sound, color, 4 3/4 in.

- Standard citation to a homepage

AMA: helping doctors help patients [Internet]. Chicago: American Medical Association; ©1995-2007 [cited 2007 Feb 22]. Available from: <http://www.ama-assn.org/>.

Footnotes and endnotes of Word must not be used in the preparation of references.

References first cited in a table or figure legend should be numbered so that they will be in sequence with references cited in the text taking into consideration the point where the table or figure is first mentioned. Therefore, those references should not be listed at the end of the reference section but consecutively as they are cited.

Insert the references here.

NOTES

Insert in this section:

-conflicts of interest (mandatory); if there is no conflict of interest, this should also be explicitly stated as follows: “The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript”

-mention of any funding, research contracts (optional)

-authors' contributions (mandatory)

-list of the members of the collective name (optional where applicable); author's name in full, middle name's initial in capital letters and surname; complete affiliation or city are optional

-contributors (optional where applicable) only when contributors are not part of a collective author

-dates of any congress where the paper has already been presented (optional)

Conflicts of interest.—

Funding.—

Authors' contributions.—

Group name.—

CASE 1:

Members of the group include the following (in alphabetical order): Name M. SURNAME; Name M. SURNAME, ...

CASE 2:

Name M. SURNAME, Name M. SURNAME already listed in the authors' byline also form part of the group name.

Members qualified as contributors include the following (in alphabetical order): Name M. SURNAME; Name M. SURNAME, ...

CASE 3:

Members qualified as authors include the following (in alphabetical order): Name M. SURNAME; Name M. SURNAME, ...

Members qualified as contributors include the following (in alphabetical order): Name M. SURNAME; Name M. SURNAME, ...

Contributors. —

Congresses.—

Acknowledgements.—

TABLES

Insert the tables in the text file.

Each table should be created with the Table menu of Microsoft Word table editor, by selecting the number of rows and columns needed. Tabulations are not allowed. Each table must be numbered in Roman numerals and accompanied by the relevant title. Each table must include heading, body and notes, if needed at the foot of the table. Tables should be referenced in the text sequentially.

Table I.— *Insert the title of the table here*

Sample table

<i>Table heading</i>	<i>Table heading</i>		
<i>Table body</i>	<i>Table body</i>	<i>Table body</i>	<i>Table body</i>
<i>Table body</i>	<i>Table body</i>	<i>Table body</i>	<i>Table body</i>

Table note:

Insert the titles of figures.

Figures should be submitted as a separate file. Figures should be referenced in the text sequentially.

TITLES OF FIGURES

Figure 1.— *Insert the titles of figures here.*